Sarepta Stock Slides on Negative Read-Through From Novartis Trial Failure

Sarepta Therapeutics (NASDAQ: SRPT) stock fell 7.6% in pre-open trading on Tuesday after a high-profile clinical trial failure from Novartis rattled investor confidence in a key neuromuscular disease area where Sarepta has a competing pipeline asset.

Novartis Trial Miss Sparks Sector Selloff

The selloff was triggered by a September 8 announcement from Novartis (NYSE: NVS) that its global Phase III HARBOR study did not meet its primary endpoint. The trial was evaluating the drug del-desiran in patients with myotonic dystrophy type 1 (DM1), a neuromuscular disease.

Novartis reported that the drug failed to show a statistically significant improvement compared to a placebo. This news had a direct competitive read-through for Sarepta, as its own drug candidate, SRP-1003, also targets DM1 using a similar siRNA mechanism aimed at reducing toxic DMPK RNA. The failure has led investors to reassess the probability of clinical success for this therapeutic approach, pressuring shares of other companies in the space, including Dyne Therapeutics (NASDAQ: DYN).

Ad

Market and Company-Specific Headwinds

The negative sentiment from the Novartis trial was compounded by a broader risk-off tone in the market. U.S. futures were mixed, with Dow Jones futures declining over 300 points, and a general aversion to growth-oriented sectors like biotechnology amplified the selling pressure on Sarepta's stock.

This development adds to existing challenges for the company. Sarepta has recently been navigating tightened 2026 revenue guidance and ongoing regulatory uncertainty surrounding its Duchenne muscular dystrophy (DMD) franchise, according to a report from Investing.com. With the Novartis news casting doubt on a meaningful pipeline asset, investors are facing another layer of uncertainty regarding the company's long-term growth prospects.